Unlock instant, AI-driven research and patent intelligence for your innovation.
Medicament for treating vitreous opacity
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of vitreous opacity and drugs, which is applied in the direction of drug combinations, pharmaceutical formulas, plant raw materials, etc., and can solve problems such as many complications, poor therapeutic effect, and decline
Inactive Publication Date: 2013-07-10
NANTONG HONGCI PHARMA
View PDF5 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Vitreous opacity is not an independent disease, but a common manifestation of many eye diseases. This disease sometimes develops rapidly, and the patient's vision rapidly declines to light perception, which brings great pain and inconvenience to life.
In addition, the vitreous itself has neither blood vessels nor nerves, and its metabolism is extremely slow. When turbidity occurs, the treatment effect is often not good
For patients with severe vitreous hemorrhage, only vitrectomy can be used, but there are many complications and easy loss of vision
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0017] Example 1, the weight ratio of raw materials: Gexianmi 6g, Angelica 8g, Dendrobium 8g, Guimu 6g, Qingzizi 6g, Rehmannia glutinosa 8g, Radix Paeoniae Alba 6g, Sangji 8g, Usnea 3g.
Embodiment 2
[0018] Example 2, the weight ratio of raw materials: Gexianmi 10g, Angelica 15g, Dendrobium 15g, Guimu 10g, Qingzizi 10g, Rehmannia glutinosa 15g, Radix Paeoniae Alba 10g, Sangji 15g, Usnea 6g.
Embodiment 3
[0019] Example 3, the weight ratio of raw materials: Gexianmi 8g, Angelica 10g, Dendrobium 10g, Guimu 8g, Qingzizi 8g, Rehmannia glutinosa 10g, Radix Paeoniae Alba 8g, Sangji 10g, Usnea 5g.
[0020] When in use, add water to decoct the traditional Chinese medicines Ge Xianmi, Angelica, Dendrobium, Guimu, Qingzizi, Rehmannia glutinosa, Radix Paeoniae Alba, Usnea and Sangjisheng twice, combine the filtrates, and take them in the morning and evening.
[0021] The effective combination and coordination of the above drugs can effectively achieve the purpose of treating vitreous opacity, and has less side effects. The above results are fully proved by the clinical data, and the relevant data are as follows, wherein the drug used in the study is the weight ratio of the bulk drug in Example 3.
[0022] 1 Objects and methods.
[0023] 1.1 Objects: From January 2009 to September 2011, 90 patients (133 eyes) had vitreous opacity caused by various reasons. Among them, there were 31 male...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a medicament for treating vitreous opacity, which can solve the treatment problem of vitreous opacity. The medicament is characterized by being processed from a variety of traditional Chinese medicines, and the formula comprises the following raw materials in parts by weight: 6-10 parts of nostoc sphaeroids kutz, 8-15 parts of Chinese angelica, 8-15 parts of dendrobium, 6-10 parts of Chinese trumpet creeper, 6-10 parts of feather cockscomb seed, 8-15 parts of radix rehmanniae preparata, 6-10 parts of white paeony root, 8-15 parts of Chinese taxillustwig and 3-6 parts of Chinese usnea. Clinical experiments prove that the medicament disclosed by the invention has the characteristics of good curative effect and higher safety for treating vitreous opacity and is worthy of clinical application and popularization.
Description
technical field [0001] The invention relates to the field of traditional Chinese medicine, in particular to a medicine for treating vitreous opacity. Background technique [0002] The normal vitreous body is a transparent gel body, which tends to degenerate with age, mainly manifested as condensation and liquefaction, that is, the transparent gel body in the vitreous body appears opaque, which is called vitreous opacities. It is a common eye disease in middle-aged and elderly people. The symptoms are smoke columnar or cloud-like dark shadows in the visual field, and the vitreous body is dusty, filamentous, flocculent, and cord-like cloudy. Vitreous opacity is not an independent disease, but a common manifestation of many eye diseases. This disease sometimes develops rapidly, and the patient's vision rapidly declines to light perception, which brings great pain and inconvenience to life. In addition, the vitreous itself has neither blood vessels nor nerves, and its metaboli...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
